Navigation Links
First Patient Treated in U.S. Clinical Study of Cohera Medical's TissuGlu® Surgical Adhesive
Date:5/1/2012

pproval_for_tissuglureg_surgical_adhesive">CE Marking approval for TissuGlu and began selling product to hospitals and surgeons in Germany in September 2011.  The company plans to expand the commercial availability of TissuGlu to additional European markets in 2012. TissuGlu has been used successfully in over 350 surgical procedures in Germany by leading plastic and reconstructive surgeons.

Currently, most patients who undergo abdominoplasty procedures and other flap procedures require the insertion of drains to remove fluids that accumulate under the skin at the surgical site. In some cases, drainage is inadequate and the excess fluid accumulation (seroma) requires additional procedures for removal. TissuGlu adheres the tissue flap created during the procedure to the underlying tissue, helping to reduce the fluid that can accumulate in the space and ultimately reducing the time to drain removal. The use of TissuGlu may shorten the length of time that drains need to be in place, leading to a more comfortable recovery and a quicker return to normal activity for patients.

About Cohera Medical
Cohera Medical, Inc.® is a leading innovator and developer of absorbable surgical adhesives and sealants. The Company's first product, TissuGlu® Surgical Adhesive, is an internal surgical adhesive for large flap surgeries, such as abdominoplasty (tummy tuck), that help eliminate or reduce fluid accumulation and the need for post surgical drains.  TissuGlu's chemical composition is resorbable, non-toxic, forms a strong bond between tissue layers and allows for natural healing, which ultimately may enable faster recovery. TissuGlu has received CE Marking approval to be sold in the European Union (EU).  Cohera Medical is also developing a unique and proprietary bowel sealant, and a strong
'/>"/>

SOURCE Cohera Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel
2. Hospira Reports First-Quarter 2012 Results
3. Rigel Announces First Quarter 2012 Financial Results
4. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
5. Luminex Corporation Reports First Quarter 2012 Results
6. Halozyme to Host First Quarter 2012 Financial Results Conference Call
7. Anthera Announces First Quarter 2012 Financial Report and Conference Call
8. Chindex International, Inc. to Report First Quarter 2012 Financial Results
9. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
10. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
11. Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... The Physician-Patient Alliance for Health & Safety recently released three ... urgently address this issue has been emphasized by The ... device alarm safety in hospitals." According to The Joint Commission ... there were 98 alarm related events reported, of which: ... resulted in permanent loss of function (13%) , 5 ...
(Date:6/19/2013)... NEW YORK , June 19, 2013   ... dedicated to finding a cure for brain cancer, today ... ) a grant to support the clinical investigation of ... a recurrent high grade glioma brain cancer (Grade 3 ... company developing novel treatments for advanced cancer, with an ...
(Date:6/19/2013)...   Nektar Therapeutics (Nasdaq: NKTR ) ... (HAL) study for NKTR-181, a first-in-class, opioid analgesic ... This slow rate of entry is designed to reduce the ... to current opioid analgesics. 1 In the study data ... placebo in "drug liking" and "feeling high" scores and had ...
Breaking Medicine Technology:Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 2Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 3Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9
... Study Showed 11 Percent Fewer RA Patients,Reported ... Therapy,Compared to Methotrexate Alone, BARCELONA, Spain, June ... one of the most common causes of,disability ... today show that,rheumatoid arthritis (RA) patients treated ...
... Influenza Conference, HIGH WYCOMBE, England, June 18, 2007 ... new flu vaccine has the,potential to protect against ... presented today by PepTcell, at the 2007,Options for ... Canada. , The pre-clinical results, which will be ...
Cached Medicine Technology:Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work,Productivity in Patients with Rheumatoid Arthritis 2Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work,Productivity in Patients with Rheumatoid Arthritis 3Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work,Productivity in Patients with Rheumatoid Arthritis 4Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work,Productivity in Patients with Rheumatoid Arthritis 5Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work,Productivity in Patients with Rheumatoid Arthritis 6Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work,Productivity in Patients with Rheumatoid Arthritis 7New Flu Vaccine From PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 2New Flu Vaccine From PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 3New Flu Vaccine From PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 4
(Date:6/19/2013)... Harris Hawaii Realtor Group has opened ... providing vacation rental management services, as well as full ... Hawaii Realtor since 1986, formed the Harris Hawaii Realty ... , Harris Hawaii offers luxury vacation rentals in Wailea. ... scenery, pristine beaches, world class golf, and of course ...
(Date:6/19/2013)... June 19, 2013 Brain not working? ... MS, explains why such seemingly minor brain problems as ... are vital red flags. They indicate the brain may ... sclerosis (MS), Alzheimer’s, Parkinson’s, stroke, and other neurological diseases. ... June 2013 by Elephant Press is now available online ...
(Date:6/19/2013)... June 19, 2013 Amber Roberson ... RWI Benefits, LLC, Native Care Health, LLC and ... of Health Underwriters’ (NAHU) new professional development course ... (PPACA). This continuing education course for agents has ... will receive eleven education credits from the Missouri ...
(Date:6/19/2013)... Advances in emergency medicine and trauma surgery have ... in the days immediately after major injuries, including ... of their injuries now are at greatest risk ... reaction known as sepsis or from inflammation-induced ... Massachusetts General Hospital (MGH) investigators that measures the ...
(Date:6/19/2013)... A new understanding of the genetic process that can ... potentially dangerous lesions for some women, and also raises ... in certain cases suggesting they could actually trigger ... analysis provides a clearer picture of the chromosomal and ... sometimes leads to chronic infection and, in less than ...
Breaking Medicine News(10 mins):Health News:Harris Hawaii Realtor Group Opens New Office in Wailea, HI 2Health News:Brain Not Working? Minor Symptoms Now Could Mean MS, Alzheimer's, or Parkinson's Later 2Health News:Brain Not Working? Minor Symptoms Now Could Mean MS, Alzheimer's, or Parkinson's Later 3Health News:RWI Benefits, LLC Becomes PPACA Certified 2Health News:Restoring appropriate movement to immune cells may save seriously burned patients 2Health News:Restoring appropriate movement to immune cells may save seriously burned patients 3Health News:Genetics of cervical cancer raise concern about antiviral therapy in some cases 2
... ... a workshop on Dried Blood Spot Sampling in the Pharmaceutical Industry: Methodology, Implementation and Best ... ... Drug Information Association (DIA) , in cooperation with PhRMA, will host a workshop on ...
... Fla., Nov. 13 Many Americans suffer from bipolar disorder ... there is another way to cope with the illness that ... of Darkness: A personal journey of embracing the bipolar opportunity" ... who was diagnosed bipolar at age 17 -- presents a ...
... CARY, N.C., Nov. 13 Cornerstone Therapeutics Inc. (Nasdaq ... developing and commercializing significant products primarily for the respiratory ... Andrew K. W. Powell, Esq. Executive Vice President, General ... will join the Company,s executive management team and manage ...
... ... published independent clinical study on Vemma, its physician formulated liquid supplement, ... (Volume 57, Number 19, October 14, 2009). The clinical study ... Product in Humans” found that Vemma is highly bioavailable, showing an ...
... ... for Wellbeing, the subscription course is aimed at optimizing health goals , ... Draper, UT (PRWEB) November 13, ... program called ZriiAware: Grow Younger, Live Longer , with the intention of helping ...
... PORTLAND, Ore. Nov. 12 Regence BlueCross BlueShield has ... the American Heart Association,s Start! movement for helping employees ... and employee wellness are important priorities at Regence," said ... providing the best workplace environment possible and helping our ...
Cached Medicine News:Health News:,DIA/PhRMA Workshop to Explore Dried Blood Spot Sampling Implementation and Advances, 2Health News:,DIA/PhRMA Workshop to Explore Dried Blood Spot Sampling Implementation and Advances, 3Health News:'Living Out of Darkness: A personal journey of embracing the bipolar opportunity' 2Health News:'Living Out of Darkness: A personal journey of embracing the bipolar opportunity' 3Health News:Cornerstone Therapeutics Appoints General Counsel 2Health News:Cornerstone Therapeutics Appoints General Counsel 3Health News:Independent Clinical Study Finds Vemma is Highly Bioavailable Showing Increase in Vitamins and Antioxidants in the Blood* 2Health News:Independent Clinical Study Finds Vemma is Highly Bioavailable Showing Increase in Vitamins and Antioxidants in the Blood* 3Health News:Independent Clinical Study Finds Vemma is Highly Bioavailable Showing Increase in Vitamins and Antioxidants in the Blood* 4Health News:Zrii Implements New Online Lifestyle Program, ZriiAware: Grow Younger, Live Longer 2Health News:Regence Recognized as an American Heart Association Start! Fit-Friendly Company 2Health News:Regence Recognized as an American Heart Association Start! Fit-Friendly Company 3
For rigid cystoscopes and rigid-, and semi-rigid ureteroscopes, these forceps have an integral handle design and a diameter of 5 Fr with a working length of 58 cm....
Fulgurating Electrode, 2 F...
Used to obtain biopsy specimens from pathological lesions in the ureter, renal pelvis, infundibula, or calyces. Supplied sterile in peel-open packages. Intended for one-time use....
Used to obtain tissue biopsy under direct vision. Cup Biopsy Forceps are designed for use through rigid or flexible endoscopes. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: